PDB81 TIME TO ADD-ON MEDICATION USE FOR PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM) WHO FAILED METFORMIN MONOTHERAPY
Qiu Y 1 , Fu AZ 2 , Radican L 1 1 Merck & Co., Inc., Whitehouse Station, NJ, USA; 2 Cleveland Clinic, Cleveland, OH, USA OBJECTIVES: Add-on medications are recommended if target glycemic goals for patients with T2DM are not achieved or sustained after initial metformin monotherapy. This study examined the time to add-on medication use after metformin monotherapy failure in clinical practice. METHODS: Selected from a large US EMR database between Janujary 1, 1997 and December 31, 2008, included patients had to be aged ≥18 years with a diagnosis of T2DM who had HbA1c ≥ 7.0% or ≥ two fasting blood glucose levels of 126 mg/dL or greater. Treatment failure was defi ned as HbA1c ≥ 7% (index date) after metformin monotherapy for at least 6 months. Baseline data were extracted during 1 year prior to the index date. Time to add-on medication use was time between index date to the fi rst add-on medication use during follow-up and was evaluated for the overall cohort and for three index HbA1c subgroups: <8%, 8-9%, and >9%. a Cox proportional hazard model was employed to determine baseline clinical and demographic characteristics associated with shorter time to add-on medication use. RESULTS: There were 12,566 patients meeting the inclusion criteria; 8656, 2175 and 1735 had index HbA1c < 8%, 8-9% and >9%, respectively. The overall mean (SD) age was 63 (12) years and 51% were female. The median time to add-on medication use was 15.7 months overall and 17.0, 13.9 and 11.3 months for patients with index HbA1c < 8%, 8-9% and >9%, respectively. Higher index A1c, greater body mass index, higher Charlson comorbidity index, younger age, males, lower LDL were signifi cantly associated with shorter time to add-on medication use (all P < 0.05). CONCLUSIONS: This indicates, in US clinical practice, it takes over a year for a diabetic patient who has suboptimal glycemic level after initial metformin monotherapy to receive add-on medications. There is room through disease management so that patients who have failed metformin monotherapy, if eligible and appropriate, receive add on therapy sooner rather than later.
PDB82 PRESCRIBED DAILY DOSES OF ONCE-DAILY LIRAGLUTIDE IN THE GERMAN STATUTORY HEALTH INSURANCE (SHI)
Schöffski O 1 , Mentrup S 2 , Lund N 3 1 Friedrich-Alexander-Universität Erlangen-Nürnberg, Nuremberg, Germany; 2 Novo Nordisk Pharma GmbH, Mainz, Germany; 3 Novo Nordisk A/S, Soeborg, Denmark OBJECTIVES: To evaluate the prescribed daily dose of liraglutide for patients in German statutory health insurances. The novel once-daily incretin analogue, liraglutide, mimics the effect of endogenous glucagon-like peptide 1 (GLP-1). Liraglutide was launched in Germany in July 2009 in a device allowing 3 different dosages (0.6 mg for initial titration; and the two maintenance doses 1.2 and 1.8 mg). The defi ned daily dose (DDD) was set by WHO at 1.2 mg. The prescribed daily dose (PDD) has not been evaluated so far. METHODS: Sampled data from German statutory health insurances (SHI) was provided by Insight Health (patient tracking data) for the period from July 2009 to March 2010 (9 months) covering about 11% of all patients in German SHI. All patients with prescriptions of liraglutide were identifi ed (n = 4,284). Patients with only one prescription and less than 4 weeks between fi rst and last date of prescription were excluded to avoid overrepresented infl uence of low dosed therapy starters (remaining patients: n = 2,118). Total number of prescribed pens was determined from fi rst to second last prescription and total consumption in mg was calculated. Number of days between fi rst and last prescription was determined and mean average consumption in mg per day was calculated. RESULTS: The mean PDD of liraglutide in 2118 patients was 1.28 mg. Sensitivity analyses including only patients with longer periods of use showed decreasing average consumption; patients with at least 10 weeks duration of treatment showed a mean daily dose of 1.25 mg. Stocking effects (prescription before package is empty) could have driven the increase in average use in the starting period and at the end of the calendar year. CONCLUSIONS: The longer patients use liraglutide the lower the observed PDDs. , 2006 and September 30, 2007 with 12 months pre-and 18 months post-index continuous enrollment were included. Treatment modifi cation was defi ned as the fi rst event of change in the treatment and was classifi ed further into three types: intensifi cation, switching or discontinuation of the index medication. The 2 cohorts were 1:1 propensity score matched on baseline demographics, clinical characteristics, and prior health care utilization. Survival analysis was used to examine time to treatment modifi cation. RESULTS: Propensity score matching resulted in inclusion of 3774 exenatide and 3774 glargine patients with a mean age of 57 years, mean Deyo Charlson Comorbidity Index score of 1.6, and with proportionately more males (54%) than females. All of the patients concomitantly used a non-index antidiabetes medication in post-index period. The 18-month discontinuation rates were 38.3% and 40.0% (P = 0.14) and the treatment intensifi cation rates were 15.9% and 26% (P < 0.0001) for exenatide and glargine, respectively. Alternatively, 14.9% of exenatide-treated patients switched therapies, compared to 10.0% of glargine-treated patients (P < 0.0001). Glargine-treated patients were 33% more likely to modify treatment than exenatide-treated patients (Hazard Ratio (HR): 1.33, P < 0.0001). Glargine-treated patients were 72% more likely to intensify their treatment (HR = 1.72, P < 0.0001), 25% more likely to discontinue (HR = 1.25, P < 0.0001), and 29% less likely to switch to new therapy (HR = 0.71, P < 0.0001) compared to exenatide. CONCLUSIONS: This analysis showed that exenatide-treated patients were less likely to modify their treatment suggesting potential longer durability with exenatide therapy. Furthermore, exenatide-treated patients were less likely to discontinue or intensify but more likely to switch their treatment than glargine-treated patients. The goal of treating acromegaly is directed at removing the tumor, preventing tumor re-growth and reducing long-term morbidity and mortality. For this purpose, different health resources are necessary. This study evaluates the disease resources and costs in Spain. METHODS: An epidemiological, prospective, naturalistic, multicentric study (30 endocrinologists) involving acromegalic patients with micro (≤10 mm) or macro (>10 mm) adenomas was performed. Patients were categorised as Surgical Group (SG) (surgery in the 6 months before inclusion or during follow-up period and somatostatin analogue (SA) treatment for <6 months during the pre-surgery period) and Medical Treatment Group (MTG) (patients receiving SA treatment for ≥6 months, with/without surgery following SA treatment). Resource data were collected from standard visits during a 2-years period. RESULTS: The study included 74 patients (56 SG and 18 MTG). Most patients were women (62%). The mean (SD) age was 49 (14) years. The annual direct acromegaly cost per patient is c9668 (c9223 SG vs. c11,054 MTG). The cost of illness was higher in patients with macroadenoma than in microadenoma (c11,053 vs. c5809), and it is increased in young patients (<40 years). Surgical procedures in acromegaly (involving hospitalization and complementary tests) constitute the 22% and 8% of the illness cost in SG and MTG patients. Additionally, hospitalizations in intensive care units (50% SG vs. 22% MTG patients), emergency visits (21% SG vs. 6% MTG) and the presence of adenoma complications (73% SG vs. 44% MTG) constitute a source of cost increment in these patients. Patients who accomplish with the most strict study clinical control criteria (GH < 1.0 and IGF-1 < 100%) showed the lowest direct cost of illness (c6169 vs. c12,990). CONCLUSIONS: The economic cost of acromegaly is dependent on the clinical control of the disease. Direct cost of illness is the half that the cost in non controlled patients.
PDB84 MANAGEMENT OF ACROMEGALY IN CLINICAL PRACTICE CONDITIONS IN SPAIN

PDB85 APPROVAL AFTER REJECTION-AN INSIGHT IN HTA RE-EVALUATIONS
Sweeney N, Andreykiv M, Wiebinga C Quintiles Consulting, Hoofddorp, The Netherlands OBJECTIVES: To gain insight into the re-evaluation process of HTA agencies after an initial rejection and identify the adaptations that led to the approval of re-submitted dossiers. METHODS: Phase I: manual search of 57 health care agencies' websites for published diabetes-related assessments (January 2007-May 2010). Phase II: the two most re-assessed drugs for which detailed information was available were selected for further evaluation (insulin glargine and exenatide). For these drugs, all reports published prior to 2007 were also included. RESULTS: Phase I identifi ed 117 relevant single technology appraisals; 18 were re-evaluations. Six agencies performed re-evaluations of the same drug after an initial rejection: CADTH, CVZ, HAS, PBAC, AHTAPol and SMC. To date, SMC evaluated 32 submissions for 13 anti-diabetic drugs, PBAC published 20 (eight drugs), CADTH 13 (four drugs), CVZ 14 (four drugs) and AHTAPol 10 (two drugs). In phase II insulin glargine (four re-submissions to PBAC and 1 to CADTH) and exenatide (two re-submissions to PBAC, 1 to CVZ and 1 to AHTAPol) were evaluated. It became clear that payers do focus on overall cost. The approach that was chosen for those two drugs was to control overall cost either by restricting access or by settling on a lower price. CVZ accepted exenatide for reimbursement only after restricting access to a subgroup of obese type 2 diabetes mellitus patients (with an ICER of c5.231). Instead of patient segmentation PBAC insisted on lowering the price for both medications (rationale for insulin glargine being concern that prescribing cannot be contained within the defi ned population). AHTAPol limited exenatide reimbursement to 50% to control prescribing rates. CONCLUSIONS: For the diabetes cases analyzed HTA agencies attempted to control health care expenditure by either lowering drug costs or by narrowing the defi nition of the target population, the latter inevitably allowing fewer patients access to the drug.
PDB86 HEALTH TECHNOLOGY ASSESSMENT OF DIABETES COMPOUNDS: THE POLISH PERSPECTIVE
Adalsteinsson JE 1 , Czech M 2 , Skrekowska-Baran I 3 , Jasik BM 1 1 Novo Nordisk A/S, Copenhagen, Denmark; 2 Department of Pharmacoeconomics, Medical University of Warsaw, Warsaw, Poland; 3 Novo Nordisk Pharma Sp, Warszawa, Poland OBJECTIVES: The AOTM in Poland was established to give MoH in Poland advice on reimbursement. The aim of this research is to create an overview of HTA reports on diabetes compounds in Poland and the results of the decision making. METHODS: A search was conducted on the webpage of AOTM (http://www.aotm.gov.pl) for HTA reports on the following products: Rosiglitazon, Pioglitazon, Sitagliptin, Vildagliptin, Saxagliptin, Exenatide, Liraglutide, Glargine, Detemir, Aspart, Glulisene and Lispro. RESULTS: Of a total of 163 reports (published between 2007 and 2010), eight reports in Polish language on diabetes were identifi ed and assessed. Two reports can be viewed as secondary assessment of regulatory safety discussions. The other six reports assessed the implementation of new diabetes compounds with assessment of effi cacy, safety and cost-effectiveness of the drugs.Two reports assessed safety concerns associated with the risk of cancer and concluded based on EMA and FDA research that no increased risk was associated with these agents. Rosiglitazone and Sitagliptin were not recommended for reimbursement due to availability of other treatments with similar effi cacy. Saxagliptin, Exenatide and Liraglutide got the recommendation to be reimbursed due to expected increase in QALYs. The fi nal report was assessing Glulisene which got the recommendation to temporary reimburse (2 years) provided that data on hard endpoints (not specifi ed in public report) and cost-effectiveness should be delivered. CONCLUSIONS: Recommendation by AOTM is supported by assessment of available RCTs, cost per life-year gained, cost per QALY, estimated budget impact for 5 years and also in some cases reports from EMEA, FDA and other HTA agencies (SMC, PBAC and CADTH). The AOTM's recommendation is not obligatory for the Polish Ministry of Health.
PDB87 STANDARDS FOR THE ASSESSMENT OF ANTIDIABETIC DRUGS-THE IQWIG PERSPECTIVE
Schweikert B 1 , John J 2 , Ringborg A 3 , Erhardt W 4 , Bleckmann A 5 , Neubauer AS 4 1 i3 Innovus, Aschheim, Germany; 2 Helmholtz Zentrum München, Neuherberg, Germany; 3 i3 Innovus, Stockholm, Sweden; 4 Bristol-Myers Squibb, München, Germany; 5 AstraZeneca, Wedel, Germany OBJECTIVES: A substantial number of new pharmaceutical treatment strategies have been introduced for the treatment of diabetes mellitus type II. The availability of these drugs for patients in different countries depends on the evaluation standards and methods applied in the various phases of drug assessment. Objective of this research was to review the requirements and criteria applied for the assessment of antidiabetic drugs along the regulatory process by EMA (Europe) and FDA (USA) for the assessment of effi cacy and safety as well as for reimbursement decisions by NICE (England) and IQWiG (Germany) and to compare their consistency, with a special focus on IQWiG's procedures. METHODS: A review of relevant current method documents and reports on evaluations of antidiabetic drugs published by IQWiG was conducted. These were compared with guidance documents issued by FDA, EMA and NICE with respect to endpoints considered in diabetes and their defi nition, criteria for the type of evidence, and potential comparators. RESULTS: Consistently, across all agencies severe and non-severe hypoglycemias were considered highly relevant. There was, however, a substantial heterogeneity in the defi nition of hypoglycaemias. The surrogate parameter HbA1C as primary endpoint was accepted by all agencies investigated apart from IQWiG. In its assessments, evidence from randomized as well as from observational studies was accepted by NICE. For safety evaluations preclinical studies were taken into consideration by EMA and FDA in addition to randomized controlled trials. IQWiG on the other hand focused exclusively on randomized controlled trials for the assessment of effectiveness as well as safety. CONCLUSIONS: There is a substantial variation of criteria applied and evidence considered relevant within the assessment process of IQWiG compared to other agencies. This might lead to regional variations in the availability of drugs. It is important to be aware of the different requirements of agencies, when designing trials and planning market access. , care improvements can be assessed by the duration between the fi rst diagnosis and the occurrence of the fi rst related complication. The aim of this longitudinal study is to investigate the direct infl uence of the DMP-based treatments on patient outcomes, measured as the postponement of diabetes related complications in a large population of DM II patients. The study also investigates how DMP inscriptions of some patients of a medical practice indirectly infl uence patient outcomes of DM II patients, who are not inscribed in a DMP, but are treated in the same practise. We argue that this indirect effect is due to physicians' learning from the DMP-based treatments in their clinics. METHODS: Using consultation data from IMS Health from a period of 25 years ) a survival analysis is applied. The data set includes 161,747 DM II patients from >1100 practices. Applying a Kaplan-MeierMethod we test for direct effects of DMPs on patient outcomes. By pooling patients by the registration year of the practice-leading physician and by focussing on their quarterly consultation rate, we test for indirect effects of DMPs on patient outcomes. RESULTS: The mean survival time (duration between fi rst diagnosis and fi rst complication) of the medical treatment of diabetics in a DMP is 14,82 years, differing signifi cantly from the 15,76 years without a DMP. These tests are controlled for following patient variables: sex, age, HbA1C, BMI and the insurance status. Learnings from DMPs, indirectly affecting DM care, signifi cantly postpone complications for younger physicians and practices with fewer diabetics. CONCLUSIONS: Contributing to assessments of DMPs, the study discusses policy implications, as it is shown that care quality is improved by physicians learning from DMPs.
PDB88 LEARNING FROM DISEASE MANAGEMENT PROGRAMMES: HOW MEDICAL TREATMENTS AND QUALITY OF DIABETIC CARE (TYPE II) IN GERMANY ARE DIRECTLY AND INDIRECTLY IMPROVED BY DMPS
PDB89 PREDICTORS OF ROUTINE MONITORING OF DIABETES CARE AMONG THE US NON-INSTITUTIONALIZED POPULATION: A RETROSPECTIVE ANALYSIS OF THE MEDICAL EXPENDITURE PANEL SURVEY (MEPS) IN 2007
Zhao Y, Fonseca V, Campbell C, Shi L Tulane University, New Orleans, LA, USA OBJECTIVES: To examine the rate and predictors of diabetes monitoring in the US. METHODS: This cross-sectional retrospective study was conducted on a representative, non-institutionalized sample of the US population, using the self-reported information from the 2007 Household Component (HC) of the MEPS. According to the American Diabetes Association (ADA) 2007 practice guidelines, proper provider monitoring is defi ned as at least two A1c tests, one eye and one foot examination annually. Health status was measured by SF-12®Version2. a logistic regression model was used to examine the predictors of proper monitoring. Differences in health status and medical expenditures between patients with and without proper monitoring were examined using t-tests. Estimates were weighted to the total population (WTP). RESULTS: Among 1,747 (WTP: 19,320,394) patients with diabetes, 80.64% had at least two A1c tests; 63.29% had an eye examination; and 67.51% had a foot examination. Thus, 63.36% patients (WTP: 14, 065, 289) 
